Oculogenex

A novel investigational gene therapy designed to stop the degeneration of central vision in patients with macular degeneration.

The company has received an SBIR Phase I Grant from the National Science Foundation, won first prize in the Winning Pitch Challenge, and sent their therapy to the International Space Station via SpaceX mission.